NASDAQ:ARTV
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc.'s revenue fell 100.0% in fiscal 2025 to $0. Free cash flow was −$79.3M, and the diluted share count rose 117.1%.Summary generated from Artiva Biotherapeutics, Inc.'s SEC filings. Latest annual report filed Mar 10, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growth−100.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−56.5%
Debt / equityn/a
Free cash flow−$79.3M
FCF marginn/a
Share count change+117.1%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 33 | 0 | 0 |
| Operating income | −31 | −67 | −90 |
| Net income | −29 | −65 | −84 |
| Free cash flow | −51 | −56 | −79 |
Recent filings
- 4Insider transaction report
Oct 7, 2026 - 4Insider transaction report
Oct 6, 2026 - 8-KDirector or officer change
Sep 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - DEF 14AProxy statement
Aug 3, 2026 - 8-KOther events
Jul 22, 2026 - 8-KDirector or officer change
May 19, 2026